Efficacy, Safety, Tolerability, and Pharmacokinetics of Long-acting Injectable Cabotegravir for HIV Pre-exposure Prophylaxis in Transgender Women: A secondary analysis of the HPTN 083 trial

Understanding the Drivers of CAB PrEP Uptake and Use among Women in sub-Saharan Africa to Build Demand for New PrEP Methods

This article from Current HIV/AIDS Reports reviews facilitators and barriers to use of injectable cabotegravir (CAB) for PrEP by women in sub-Saharan Africa.

Global Acute HIV Infection Algorithm Job Aids for Providers

This tool can assist providers in assessing acute HIV infection (AHI) in clients using oral PrEP, PrEP ring, and CAB PrEP by offering guidance through three steps: HIV testing, recent exposure to HIV assessment, and AHI assessment. Providers are encouraged to use clinical judgement and defer to national guidance as needed.

Daily Oral PrEP, PrEP Ring, and CAB PrEP Template Guidelines (Spanish)

The intent of this document is to provide adaptable guidelines to support the development and adoption of national guidelines that align with World Health Organization (WHO) pre-exposure prophylaxis (PrEP) recommendations and guidance, including those for tenofovir disoproxil fumarate (TDF)-based oral PrEP, the monthly dapivirine vaginal ring (“PrEP ring” or “the ring”), and injectable cabotegravir (CAB…

HIV Prevention User Journey Tool

The HIV Prevention Journey Tool was developed to support adolescent girls and young women to explore methods that would align with their lifestyle, needs and personal preferences; and support healthcare providers to provide informed counseling based on client needs. The digital tool, which has been optimized for use on mobile devices, can be accessed here.…

2024 Q3 Global PrEP Tracker

AVAC’s Global PrEP Tracker offers two views on PrEP uptake around the world. Visit data.prepwatch.org for a dynamic map-based tool to explore trends in oral PrEP use globally as countries introduce and scale up PrEP programs. For insights on the full scope of PrEP use around the world, the PrEP Tracker as a spreadsheet offers…

Oral PrEP, PrEP Ring, and CAB PrEP Template Guidelines (English)

The intent of this document is to provide adaptable guidelines to support the development and adoption of national guidelines that align with World Health Organization (WHO) pre-exposure prophylaxis (PrEP) recommendations and guidance, including those for tenofovir disoproxil fumarate (TDF)-based oral PrEP, the monthly dapivirine vaginal ring (“PrEP ring” or “the ring”), and injectable cabotegravir (CAB…

Implementation Plan for the Introduction of the PrEP Ring and Long-acting Injectable Cabotegravir for HIV Prevention – Eswatini, August 2024

CAB PrEP Introduction Situation Analysis – South Africa – 2024

This document summarizes findings from the national situation analysis that can support the creation of a national biomedical HIV prevention platform.

Dynamic Choice HIV Prevention with Cabotegravir Long-acting Injectable in Rural Uganda and Kenya: A randomised trial extension

This article from The Lancet HIV discusses the results of the SEARCH dynamic choice study conducted in Kenya and Uganda, comparing outcomes between one group offered a choice between oral PrEP, post-exposure prophylaxis, and cabotegravir for PrEP, and a second group receiving the standard of care.

Access Workbook for Cabotegravir for PrEP, Dapivirine Vaginal Ring, and Lenacapavir for PrEP

This workbook, compiled by the Global Fund, contains key access information relating to cabotegravir (CAB) for PrEP, the dapivirine vaginal ring (DVR), and lenacapavir (LEN) for PrEP for all lower and middle income countries, including eligibility for Global Fund support, PEPFAR support status, regulatory status of CAB for PrEP and the DVR, access to non-profit…